ArticleThe Journal of pharmacology and experimental therapeutics2012
Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys.
Article in The Journal of pharmacology and experimental therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Effects of nicotinic antagonists on working memory performance in young rhesus monkeys.Neurobiology of learning and memory · 2021Article
- Effects of chronic treatment with bupropion on self-administration of nicotine + cocaine mixtures in nonhuman primates.Experimental and clinical psychopharmacology · 2020Article
- More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.Pharmacological reviews · 2020Review
- Nicotine-like discriminative stimulus effects of acetylcholinesterase inhibitors and a muscarinic receptor agonist in Rhesus monkeys.Drug development and industrial pharmacy · 2019Article
- Ultrapotent chemogenetics for research and potential clinical applications.Science (New York, N.Y.) · 2019Article
- Discriminative stimulus effects of mecamylamine and nicotine in rhesus monkeys: Central and peripheral mechanisms.Pharmacology, biochemistry, and behavior · 2019Article
- Green tobacco sickness: mecamylamine, varenicline, and nicotine vaccine as clinical research tools and potential therapeutics.Expert review of clinical pharmacology · 2019Review
- Rapid nicotine tolerance and cross-tolerance to varenicline in rhesus monkeys: Drug discrimination.Experimental and clinical psychopharmacology · 2018Article
- Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys.The Journal of pharmacology and experimental therapeutics · 2018Article
- Nicotine as a discriminative stimulus for ethanol use.Drug and alcohol dependence · 2018Article
- The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pANeuropharmacology · 2017Article
- Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily.British journal of pharmacology · 2016Article
- Effects of continuous nicotine treatment and subsequent termination on cocaine versus food choice in male rhesus monkeys.Experimental and clinical psychopharmacology · 2015Article
- Effects of the Nanoparticle-Based Vaccine, SEL-068, on Nicotine Discrimination in Squirrel Monkeys.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Article
- Determination of behaviorally effective tobacco constituent doses in rats.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2015Article
- Effect of nicotine on the structure of cochlea of guinea pigs.Anatomy & cell biology · 2014Article
- The discriminative stimulus effects of mecamylamine in nicotine-treated and untreated rhesus monkeys.Behavioural pharmacology · 2014Article
- Effects of the nicotinic acetylcholine receptor antagonist mecamylamine on the discriminative stimulus effects of cocaine in male rhesus monkeys.Experimental and clinical psychopharmacology · 2014Article
- Methamphetamine-like discriminative-stimulus effects of nicotinic agonists.The Journal of pharmacology and experimental therapeutics · 2014Article
- Patterns of nicotinic receptor antagonism II: cardiovascular effects in rats.Drug and alcohol dependence · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
This study examined mechanisms by which nicotine (1.78 mg/kg base s.c.) produces discriminative stimulus effects in rhesus monkeys. In addition to nicotine, various test compounds were studied including other nicotinic acetylcholine receptor agonists (varenicline and cytisine), antagonists [mecamylamine and the α4β2 receptor-selective antagonist dihydro-β-erythroidine (DHβE)], a nicotinic acetylcholine receptor antagonist/indirect-acting catecholamine agonist (bupropion), and non-nicotinics (cocaine and midazolam). Nicotine, varenicline, and cytisine dose-dependently increased drug-lever responding; the ED(50) values were 0.47, 0.53, and 39 mg/kg, respectively. Bupropion and cocaine produced 100% nicotine-lever responding in a subset of monkeys, whereas mecamylamine, DHβE, and midazolam produced predominantly vehicle-lever responding. The training dose of nicotine resulted in 1128 ng/ml cotinine in saliva. Mecamylamine antagonized the discriminative stimulus effects of nicotine and varenicline, whereas DHβE was much less effective. Nicotine and varenicline had synergistic discriminative stimulus effects. In monkeys responding predominantly on the vehicle lever after a test compound (bupropion, cocaine, and midazolam), that test compound blocked the nicotine-discriminative stimulus, perhaps reflecting a perceptual-masking phenomenon. These results show that nicotine, varenicline, and cytisine produce discriminative stimulus effects through mecamylamine-sensitive receptors (i.e., nicotinic acetylcholine) in primates, whereas the involvement of DHβE-sensitive receptors (i.e., α4β2) is unclear. The current nicotine-discrimination assay did not detect a difference in agonist efficacy between nicotine, varenicline, and cytisine, but did show evidence of involvement of dopamine. The control that nicotine has over choice behavior can be disrupted by non-nicotinic compounds, suggesting that non-nicotinics could be exploited to decrease the control that tobacco has over behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.